Keros Therapeutics (KROS) Operating Income (2019 - 2025)
Keros Therapeutics (KROS) posted Operating Income of -$29.3 million for Q4 2025, down 90.26% on a QoQ basis from -$15.4 million in Q3 2025, and up 45.04% year-over-year from -$20.2 million in Q4 2024.
Keros Therapeutics (KROS) Operating Income (2019 - 2025) Analysis & Trends
Keros Therapeutics' Operating Income history runs 7 years deep, the most recent figure standing at -$29.3 million for Q4 2025.
- Quarterly Operating Income rose 45.04% year-over-year to -$29.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $67.6 million (up 132.05% YoY) and the FY2025 annual result came in at $67.6 million, up 132.05% from the prior year.
- Operating Income was -$29.3 million for Q4 2025 at Keros Therapeutics, down from -$15.4 million in the prior quarter.
- Across five years, Operating Income topped out at $152.0 million in Q1 2025 and bottomed at -$58.7 million in Q3 2024.
- A 5-year average of -$24.2 million and a median of -$31.3 million in 2022 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income plunged 556.8% — and 2025, when it surged 413.59%.
- Keros Therapeutics' Operating Income stood at -$4.9 million in 2021, then plunged by 556.8% to -$32.0 million in 2022, then plunged by 45.35% to -$46.5 million in 2023, then slipped by 14.64% to -$53.3 million in 2024, then surged by 45.04% to -$29.3 million in 2025.
- Business Quant data shows KROS's Operating Income at -$29.3 million in Q4 2025, -$15.4 million in Q3 2025, and -$39.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Keros Therapeutics | 377.42 Mn | 90.02 Mn | - | -29.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -29.27 Mn |
| Sep 30, 2025 | -15.38 Mn |
| Jun 30, 2025 | -39.82 Mn |
| Mar 31, 2025 | 152.04 Mn |
| Dec 31, 2024 | -53.25 Mn |
| Sep 30, 2024 | -58.66 Mn |
| Jun 30, 2024 | -50.44 Mn |
| Mar 31, 2024 | -48.48 Mn |
| Dec 31, 2023 | -46.46 Mn |
| Sep 30, 2023 | -43.28 Mn |
| Jun 30, 2023 | -41.34 Mn |
| Mar 31, 2023 | -38.87 Mn |
| Dec 31, 2022 | -31.96 Mn |
| Sep 30, 2022 | -27.98 Mn |
| Jun 30, 2022 | -30.73 Mn |
| Mar 31, 2022 | -24.13 Mn |
| Dec 31, 2021 | -4.87 Mn |
| Sep 30, 2021 | -20.20 Mn |
| Jun 30, 2021 | -15.54 Mn |
| Mar 31, 2021 | -15.77 Mn |